🇺🇸 FDA
Patent

US 11021424

Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers

granted A61KA61K31/355A61P

Quick answer

US patent 11021424 (Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers) held by PTC THERAPEUTICS, INC. expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PTC THERAPEUTICS, INC.
Grant date
Tue Jun 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
85
CPC classes
A61K, A61K31/355, A61P, A61P13/02, A61P21/00